KP-673

KP-673 is an orally bioavailable, small molecule covalent inhibitor specifically targeting the **GTPase KRas** protein with the **G12C mutation**. Developed by **SciClone Pharmaceuticals**, the drug is designed to treat patients with **advanced resistant non-small cell lung cancer (NSCLC)** and other solid tumors harboring this specific oncogenic driver. The KRAS G12C mutation, characterized by a glycine-to-cysteine substitution at codon 12, locks the KRAS protein in a constitutively active, GTP-bound state, which triggers continuous downstream signaling through the MAPK/ERK pathway to promote tumor growth. KP-673 works by selectively and irreversibly binding to the cysteine residue of the inactive, GDP-bound form of the KRAS G12C protein, effectively trapping it in its inactive conformation and halting oncogenic signaling. It is currently being evaluated in Phase 1 clinical trials to assess its safety, pharmacokinetics, and preliminary anti-tumor activity in patients with advanced malignancies.

Other names

KP673KP-673KP 673